Status | Study |
Recruiting |
Study Name: Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Condition: Uveal Melanoma Date: 2013-09-17 Interventions: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA |
Completed |
Study Name: New Biopsy Technique for Uveal Melanoma Condition: Uveal Melanoma Date: 2013-08-13 |
Terminated |
Study Name: A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Condition: Uveal Melanoma Date: 2013-02-21 Interventions: Drug: AEB071 Twice-daily doses |
Recruiting |
Study Name: Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Condition: Uveal Melanoma Date: 2011-09-15 |
Active, not recruiting |
Study Name: Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Condition: Uveal Melanoma Date: 2011-09-06 Interventions: Drug: AEB071 |
Active, not recruiting |
Study Name: A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Condition: Uveal Melanoma Date: 2011-06-14 Interventions: Drug: Placebo two tablets in t |
Completed |
Study Name: RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Condition: Uveal Melanoma Date: 2010-12-01 Interventions: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR Patients will be treated with SOM-230 (pasireotid |
Completed |
Study Name: Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Condition: Intraocular Melanoma Date: 2010-10-07 Interventions: Biological: bevacizumab Drug: temozolomide |
Recruiting |
Study Name: Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Condition: Uveal Melanoma Date: 2009-12-15 Interventions: Drug: CP-675,206 Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of eve |
Completed |
Study Name: Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye Condition: Intraocular Melanoma Date: 2009-08-05 Interventions: Genetic: fluorescence in situ hybridization |